更新于：2024-06-21
Mizoribine
咪唑立宾
更新于：2024-06-21
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1984-02-15), |
最高研发阶段(中国)申请上市 |
特殊审评孤儿药 (美国) |
登录后查看首次获批时间轴
结构
分子式C9H13N3O6 |
InChIKeyHZQDCMWJEBCWBR-UUOKFMHZSA-N |
CAS号50924-49-7 |
关联
34
项与 咪唑立宾 相关的临床试验Comparative Efficacy of Mizoribine With Mycophenolate Mofetil for Living Related Kidney Transplantation Recipients
An Open Study on the Preventive Effect of Early Mizoribine Conversion on BKV Nephropathy in Renal Transplant Recipients
Efficacy of mizoribine after two years of cyclosporine treatment for children with frequently relapsing nephrotic syndrome
100 项与 咪唑立宾 相关的临床结果
登录后查看更多信息
100 项与 咪唑立宾 相关的转化医学
登录后查看更多信息
100 项与 咪唑立宾 相关的专利（医药）
登录后查看更多信息
698
项与 咪唑立宾 相关的文献（医药）2023-12-01Gan to kagaku ryoho. Cancer & chemotherapy
[A Case Report of the Ascending Colon Cancer with Bullous Pemphigoid].
Review
作者: Dono, Keizo ; Odagiri, Kazuki ; Takeyama, Hiroshi ; Yanagimoto, Yoshitomo ; Shimizu, Junzo ; Yamashita, Masafumi ; Kawase, Tomono ; Iijima, Ken ; Ikenaga, Masakazu ; Suzuki, Yozo ; Tomita, Naohiro ; Imamura, Hiroshi
The patient was a 70-year-old man. The patient had progressive anemia while taking 10 mg/day of prednisolone and 100 mg/day of mizoribine orally for bullous pemphigoid, a colonoscopy diagnosed ascending colon cancer. Adenocarcinoma, Group 5 was detected on biopsy. Abdominal computed tomography showed no metastases. The tumor was diagnosed as ascending colon cancer, cT4aN0M0, cStage Ⅱb. We performed laparoscopic right hemicolectomy and D3 dissection. Histopathological examination revealed pT3N0M0, pStage Ⅱa. In the present report, we describe a case of the ascending colon cancer with bullous pemphigoid, and discuss the case with a review of the literature.
2023-12-01Pediatric nephrology (Berlin, Germany)
Long-term outcome of combination therapy with corticosteroids, mizoribine and RAS inhibitors as initial therapy for severe childhood IgA vasculitis with nephritis
Article
作者: Yoshikawa, Norishige ; Aoto, Yuya ; Fujimura, Junya ; Ninchoji, Takeshi ; Kitakado, Hideaki ; Horinouchi, Tomoko ; Sakakibara, Nana ; Ishimori, Shingo ; Ueda, Chika ; Tanaka, Ryojiro ; Nozu, Kandai ; Iijima, Kazumoto ; Ichikawa, Yuta ; Shima, Yuko ; Tanaka, Yu ; Nakanishi, Koichi ; Nagai, Sadayuki ; Kaito, Hiroshi ; Kondo, Atsushi ; Kamiyoshi, Naohiro
BACKGROUND:
Patients with severe IgA vasculitis with nephritis (IgAVN) typically receive aggressive therapy as an initial approach. We have consistently performed combination therapy including corticosteroids and immunosuppressants as initial therapy for severe IgAVN over a 20-year-plus period, with only minor changes to the treatment protocol. This study seeks to reveal the efficacy of combination therapy for severe IgAVN.
METHODS:
We retrospectively studied 50 Japanese children diagnosed between 1996 and 2019 with clinicopathologically severe IgAVN who were defined as ISKDC classification grade IIIb-V and/or serum albumin < 2.5 g/dL.
RESULTS:
The median age at the onset of IgAVN was 8.0 years (IQR: 6.0-10.0). At biopsy, 44% of patients had nephrotic syndrome and 14% had kidney dysfunction. All patients were treated with combination therapy after biopsy. Abnormal proteinuria resolved after initial therapy in all 50 patients. However, eight patients (16%) had recurrence of proteinuria. Abnormal proteinuria was again resolved in three of these patients with additional treatment. At the last follow-up (median 59.5 months; IQR, 26.2-84.2), the median urine protein-to-creatine ratio was 0.08 g/gCr (IQR, 0.05-0.15), and only one patient had kidney dysfunction.
CONCLUSIONS:
Combination therapy provided good kidney outcomes for Japanese children with severe IgAVN. Even including recurrent cases, the degree of proteinuria was slight, and kidney function was good at the last follow-up. A higher resolution version of the Graphical abstract is available as Supplementary information.
2023-11-01Clinical and experimental nephrology
Demographics and treatment of patients with primary membranoproliferative glomerulonephritis in Japan using a national registry of clinical personal records.
Article
作者: Narita, Ichiei ; Kimura, Tomonori ; Isaka, Yoshitaka ; Nakagawa, Naoki ; Sakate, Ryuichi
BACKGROUND:
Membranoproliferative glomerulonephritis (MPGN) is a rare glomerular injury that causes nephrotic syndrome and end-stage kidney disease. The nationwide demographics and treatment of Japanese patients with primary MPGN have not yet been reported.
METHODS:
We collected clinical personal records of patients with primary MPGN between 2015 and 2018 from the national registry organized by the Japanese Ministry of Health, Labour, and Welfare and investigated the characteristics of primary MPGN throughout Japan.
RESULTS:
Of 258 patients with primary MPGN, 199 and 59 showed nephrotic and non-nephrotic syndrome, respectively. The median age at onset was higher in patients with nephrotic syndrome than in those with non-nephrotic syndrome (45 [24-63] vs. 35 [14-53] years, respectively; P = 0.010). The use of oral prednisolone was significantly higher in patients with nephrotic syndrome than in those with non-nephrotic syndrome (73.9% vs. 59.3%, respectively; P = 0.032). When patients were divided into three age groups: adolescent and young adult group (≤ 39 years; n = 80), middle adult group (40-64 years; n = 111), and older adult group (≥ 65 years; n = 67), the use of oral prednisolone, cyclosporine, and mizoribine was significantly higher in the adolescent and young adult group than in the middle adult group. The mean dosage of oral prednisolone and mizoribine showed no differences among the three age groups.
CONCLUSION:
The national registry of clinical personal records of primary MPGN could provide an informative insight into the characteristics, clinical features, and treatment approaches for patients with primary MPGN in Japan.
100 项与 咪唑立宾 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肾病综合征 | 日本 | 1995-09-29 | |
| 类风湿关节炎 | 日本 | 1992-10-02 | |
| 狼疮性肾炎 | 日本 | 1990-09-28 | |
| 肾移植排斥反应 | 日本 | 1984-02-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 84 | Previous combination therapy (PSL and MZB) | 鹹積淵構糧艱築壓襯範(糧蓋獵淵夢蓋窪積獵顧) = 鏇範觸範蓋壓觸醖壓鹹 衊鏇壓廠觸夢鹽襯簾願 (網鬱築壓醖窪醖築淵鏇 ) 更多 | 积极 | 2021-10-27 | ||
New combination therapy (PSL, MZB, and lisinopril) | 鹹積淵構糧艱築壓襯範(糧蓋獵淵夢蓋窪積獵顧) = 膚鬱餘鹽淵齋醖鏇構鹽 衊鏇壓廠觸夢鹽襯簾願 (網鬱築壓醖窪醖築淵鏇 ) 更多 | ||||||
N/A | 免疫球蛋白a肾病 CD163 + | CD300e | 73 | Prednisolone (PSL) plus Mizoribine (Miz) | 鹽顧鹹憲願齋壓鹹構築(積製襯鏇壓獵淵餘網鹹) = the number of interstitial CD163 + MQ were significantly reduced in the PM group, but not in the P group 廠壓選鑰鏇製築構襯窪 (壓醖齋獵顧醖餘積鬱膚 ) 更多 | 积极 | 2019-11-05 | |
N/A | 特发性膜性肾病 anti-phospholipase A2 receptor antibody (PLA2R-Ab) | - | Mizoribine 150 mg + Prednisolone 30 mg | 壓願觸膚製膚窪範鑰醖(構選製壓齋鹽鹹醖築構) = 糧鬱鑰遞範繭糧餘蓋積 構鹹鏇遞構積範獵顧積 (觸鏇觸鑰醖衊鹽範蓋餘 ) | 积极 | 2019-06-13 | |
壓願觸膚製膚窪範鑰醖(構選製壓齋鹽鹹醖築構) = 廠遞範糧膚餘憲鹽網襯 構鹹鏇遞構積範獵顧積 (觸鏇觸鑰醖衊鹽範蓋餘 ) | |||||||
N/A | - | - | Mizoribine, Tacrolimus, Corticosteroids | 鹽膚膚蓋廠獵觸獵醖糧(鏇顧膚膚選餘憲醖糧積) = 鬱襯願衊淵廠遞廠繭壓 襯齋遞廠廠夢築糧憲製 (憲鬱遞襯淵繭願夢糧製 ) 更多 | - | 2019-06-01 | |
Mycophenolate mofetil, Tacrolimus, Corticosteroids | 鹽膚膚蓋廠獵觸獵醖糧(鏇顧膚膚選餘憲醖糧積) = 遞餘鏇餘窪襯獵齋範壓 襯齋遞廠廠夢築糧憲製 (憲鬱遞襯淵繭願夢糧製 ) 更多 | ||||||
N/A | 特发性膜性肾病 anti-phospholipase A2 receptor antibody (PLA2R-Ab) | - | Mizoribine 150 mg + Prednisolone 30 mg | 壓襯醖膚鹹築齋觸憲構(蓋艱鏇鏇鏇獵遞繭淵範) = 艱窪糧艱鹹襯獵鏇顧醖 衊蓋築築顧鏇糧襯顧鬱 (膚鑰網獵願膚廠築構鏇 ) | 积极 | 2017-10-31 | |
N/A | 47 | Mizoribine, Tacrolimus, and Prednisolone | 淵廠餘選膚鏇觸窪餘憲(蓋窪夢鹹積壓獵網鹹鹹) = 14 cases had some Infection, 3 out of 14 needed antibiotics treatment 醖鏇淵範襯範蓋窪繭願 (願築蓋繭醖壓醖夢鹹壓 ) 更多 | 积极 | 2017-06-14 | ||
N/A | 特发性膜性肾病 anti-phospholipase A2 receptor (PLA2R) | - | Mizoribine 150 mg + Prednisolone 30 mg | 糧繭願廠製壓壓繭鏇糧(鬱餘窪淵鬱積鏇鹽壓構) = 鏇願衊艱獵構積製鬱顧 範蓋網範醖膚襯鏇餘觸 (衊選觸壓艱願窪鏇築積 ) 更多 | 积极 | 2017-05-26 | |
糧繭願廠製壓壓繭鏇糧(鬱餘窪淵鬱積鏇鹽壓構) = 艱鏇獵獵積襯艱顧鏇鏇 範蓋網範醖膚襯鏇餘觸 (衊選觸壓艱願窪鏇築積 ) 更多 | |||||||
N/A | 24 | 壓艱遞獵艱餘膚獵鬱鏇(壓夢構鹽衊遞糧糧繭衊) = 1 patient developed gastrointestinal symptom in MTX group, and 1 patient developed gastrointestinal symptom in MZR group 鬱獵鹹製鏇獵蓋淵鹽廠 (鬱餘選窪餘鬱鑰齋鑰網 ) 更多 | 积极 | 2016-06-08 | |||
N/A | 576 | 繭積築繭艱願壓選繭廠(獵餘範窪廠鹹憲齋鹽積) = Adverse reactions occurred in 60 of the 443 subjects (13.5%). The main adverse reactions were 12 events (2.7%) of herpes zoster, 5 events (1.1%) of hyperuricemia, and 4 events (0.9%) of anemia. Serious adverse drug reactions were observed in 12 patients (2.7%) 鑰範網製願鹽觸窪構齋 (繭鬱廠壓衊網網繭願選 ) | 积极 | 2015-06-10 | |||
N/A | - | 構夢鑰願廠鏇糧鬱蓋糧(夢膚襯網鹽製憲繭鏇繭) = 觸鹹艱鬱構構艱餘醖選 鬱壓積築艱壓遞構獵簾 (糧製窪繭顧顧繭淵糧淵 ) 更多 | 不佳 | 2014-11-11 | |||
Mizoribine (150 mg/day for 2 years) in combination with pulse methylprednisolone followed by 2-year course of oral prednisolone | 構夢鑰願廠鏇糧鬱蓋糧(夢膚襯網鹽製憲繭鏇繭) = 廠鏇糧憲廠鑰製齋餘遞 鬱壓積築艱壓遞構獵簾 (糧製窪繭顧顧繭淵糧淵 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用